Literature DB >> 17606209

Management of hepatocellular carcinoma.

Ana Carolina Del Pozo1, Patricia López.   

Abstract

Hepatocellular carcinoma is the fifth most common cancer in the world and is the third cause of cancer-related death with varying prevalence according to endemic risk factors. Despite therapeutic advances, there has not been significant improvement in the overall survival of patients who have hepatocellular cancer in the last 2 decades. Treatment selection should be based on tumor characteristics and the underlying liver disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606209     DOI: 10.1016/j.cld.2007.04.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  7 in total

1.  Pancreatic injury after major hepatectomy: a study in a porcine model.

Authors:  Nikolaos Arkadopoulos; Constantinos Nastos; George Defterevos; Konstantinos Kalimeris; Nikolaos Papoutsidakis; Ioanna Andreadou; Tzortzis Nomikos; Agathi Pafiti; George Fragulidis; Emmanuel Economou; Panagiotis Varsos; Georgia Kostopanagiotou; Vassilios Smyrniotis
Journal:  Surg Today       Date:  2011-11-11       Impact factor: 2.549

2.  Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.

Authors:  Hong-Bo Huan; Wan-Yee Lau; Feng Xia; Kuan-Sheng Ma; Ping Bie
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Embolotherapy in the management of hepatocellular carcinoma.

Authors:  Alireza Mojtahedi; Xiaoming Yang; Gaurav K Goswami
Journal:  Semin Intervent Radiol       Date:  2008-09       Impact factor: 1.513

4.  Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study.

Authors:  Mustafa Vali; Josephina A Vossen; Manon Buijs; James M Engles; Eleni Liapi; Veronica Prieto Ventura; Afsheen Khwaja; Obele Acha-Ngwodo; Shanmugasundaram Ganapathy-Kanniappan; Ganapathy Shanmugasundaram; Labiq Syed; Richard L Wahl; Jean-Francois H Geschwind
Journal:  J Pharmacol Exp Ther       Date:  2008-06-30       Impact factor: 4.030

5.  Silencing of WWP2 inhibits adhesion, invasion, and migration in liver cancer cells.

Authors:  Yong Qin; Sheng-Qian Xu; De-Biao Pan; Guan-Xiong Ye; Cheng-Jun Wu; Shi Wang; Chao-Jun Wang; Jin-Yan Jiang; Jing Fu
Journal:  Tumour Biol       Date:  2015-12-10

6.  Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis.

Authors:  Chaojie Liang; Yingchen Xu; Guangming Li; Tuanjie Zhao; Feng Xia; Guanqun Li; Dongxin Zhang; Jixiang Wu
Journal:  Onco Targets Ther       Date:  2017-01-18       Impact factor: 4.147

7.  Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress.

Authors:  Qianqian Zhang; Weiqian Chen; Xiuling Lv; Qiaoyou Weng; Minjiang Chen; Ri Cui; Guang Liang; Jiansong Ji
Journal:  Front Pharmacol       Date:  2019-10-14       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.